Metastatic Breast Cancer — Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Citation(s)
A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab